A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501531-16-00

Acronym

MK-3475-975

Enrollment

191

Registered

2023-03-14

Start date

2020-01-24

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal carcinoma

Brief summary

Overall Survival (OS), Event-free Survival (EFS)

Detailed description

Number of participants with an adverse event (AE), Number of participants discontinuing study treatment due to an adverse event (AE)

Interventions

DRUGOXALIPLATIN

DRUGFLUOROURACIL

DRUGCALCIUM FOLINATE

DRUGCISPLATIN

DRUGPlacebo to Keytruda - saline

DRUGCALCIUM LEVOFOLINATE

DRUGFOLINIC ACID

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Number of participants with an adverse event (AE), Number of participants discontinuing study treatment due to an adverse event (AE)	—

Primary

Measure	Time frame
Overall Survival (OS), Event-free Survival (EFS)	—

Countries

Belgium, Czechia, Denmark, Estonia, France, Germany, Hungary, Italy, Portugal, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026